Exhibit 99.2

FOR IMMEDIATE RELEASE

Oragenics Announces Financing Commitment of $600,000

ALACHUA, FL (January 11, 2006): Oragenics, Inc. (AMEX:ONI) announced today that
it has entered into a definitive agreement for equity based financing of up to
$600,000 from a group of accredited investors that include board members and
executive management of the Company. The agreement provides for the sale of up
to 1,500,000 newly issued shares of common stock at a price of $0.40 per share
and the issuance of an equal number of warrants to purchase shares of common
stock that will be exercisable at $0.60 per share. The transaction is expected
to close by February 8, 2006.

Last month the Company closed on a round of financing totaling $1.175 million on
terms similar to the investment currently being announced. As stated by
Oragenics' President and CEO, Dr. Robert Zahradnik, "This financing allows the
Company to continue to advance clinical and preclinical work on our lead
programs. I believe this added investment reflects growing confidence by
investors in the underlying technology of the Company."

Neither the shares of common stock, nor the shares of common stock underlying
the warrants are registered under the Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. However, the company will
be obligated to file a resale registration statement with the Securities and
Exchange Commission relating to the shares of common stock to be issued in the
transaction and the shares of common stock to be issued upon exercise of the
warrants within forty five days of the closing. Oragenics plans to use the funds
raised to support the clinical development of the company's various technologies
and for general corporate purposes.

In an unrelated event, Oragenics' Board of Directors re-elected Dr. Robert
Zahradnik as a Director of the Company on January 6, 2006. Dr. Zahradnik had
resigned his Board position earlier in 2005 so as to comply with the American
Stock Exchange's small business required ratio of at least 50% of the board
being independent board members. As a result of Dr. Zahradnik's re-election, the
Board will now consist of three independent members and two Company executives
including Dr. Zahradnik.

About Oragenics

Oragenics is focused on the development of novel technologies and products to
address significant, unmet medical needs. Oragenics' strategy is to license and
develop products through human proof-of-concept studies prior to partnering with
major pharmaceutical, biotechnology or healthcare product firms for advanced
clinical development and commercialization. Upon completion of the private
placement financing Oragenics plans to continue its development of the following
products, which address potentially major market opportunities:
      o     SMaRT Replacement Therapy is a single, painless topical treatment
            that has the potential to offer life-long protection from most tooth
            decay.


      o     MU 1140 is a novel antibiotic with activity against many
            Gram-positive bacteria including multidrug resistant Staphylococcus
            aureus and Enterococcus faecalis. MU 1140 has a number of other
            characteristics that suggest its potential use in the treatment of a
            variety of infectious diseases.

      o     Probiora 3 Oral Probiotic Treatment employs naturally occurring
            beneficial bacteria to promote oral and periodontal health. Such
            products may be marketed without the need for extensive regulatory
            filings in certain markets. Oragenics plans to conduct a human study
            in early 2006 to support the commercialization of Probiora 3. For
            more information about Oragenics, please consult the company's
            website at www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to our
ability to successfully close on the above described private placement, those
set forth in our most recently filed annual report on Form 10-KSB and quarterly
report on Form 10-QSB, and other factors detailed from time to time in filings
with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.